The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy-Reference-Cited by-同舟云学术

The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy

Published:2017-10-13 Issue: Volume: Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:mol clin onc

Author:

Furubayashi Nobuki¹,Negishi Takahito¹,Yamashita Takuya¹,Kusano Shuhei¹,Taguchi Kenichi²,Shimokawa Mototsugu³,Nakamura Motonobu¹

Affiliation:

1. Department of Urology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811‑1395, Japan

2. Department of Pathology, National Kyushu Cancer Center, Fukuoka, Fukuoka 811‑1395, Japan

3. Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Fukuoka 811‑1395, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer;Current Oncology;2021-09-29

2. Paclitaxel and carboplatin chemotherapy after platinum‑based chemotherapy and pembrolizumab for metastatic urothelial carcinoma;Molecular and Clinical Oncology;2021-03-08

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

;Research and Reports in Urology;2020-10

4. Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3;In Vivo;2019